Nov 7 (Reuters) - Gilead Sciences GILD.O said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
((Mariam.ESunny@thomsonreuters.com;))